Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

NASDAQ:ENTA

Enanta Pharmaceuticals, Inc.

Last Close

10.90

25/09 14:39

Market Cap

309.22M

Beta: 0.38

Volume Today

8.20K

Avg: 179.09K

PE Ratio

−1.94

PFCF: −2.33

Filings Not Available